LL-37
LL-37 is a human cathelicidin — a host-defense peptide produced natively in the body — with broad-spectrum antimicrobial, wound-healing, and immunomodulatory properties. There is no approved indication; every human application is off-label and compounded. Structured community data on dosing and cycling is absent, which means this peptide sits at a point where the underlying biology has documented properties but the human-use picture — protocols, practical tolerability, what results people actually see — is largely uncharted.
Research Evidence
Evidence shape
The evidence tier for LL-37 is low, confined to two mapped indications: a thin, exploratory single trial in diabetic foot ulcers and a separate track of animal-only mechanistic research. No human study has run to completion, and the registered record offers only one linked publication. The entire space sits in the preclinical or single-trial long-tail, meaning no indication has been pursued at the scale or depth required for clinical confidence.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How LL-37 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Frequency
- daily
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
1 completed trial identified; trial dosing not reliably extracted from registry data.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for LL-37, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.